Overview

Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33

Status:
Unknown status
Trial end date:
2021-08-20
Target enrollment:
Participant gender:
Summary
This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients, and to Evaluate the Safety and Preliminary Efficacy in Advanced esophagus canver and Squamous cell carcinoma of the esophageal junction patients
Phase:
Phase 1
Details
Lead Sponsor:
Haihe Biopharma Co., Ltd.
ShangHai HaiHe Pharmaceutical